|
**Overview**: Anti-Synthetase Syndrome Panel**Introduction**: The Anti-Synthetase Syndrome Panel is a diagnostic tool designed to screen for anti-synthetase syndrome using serum samples. In India, anti-synthetase syndrome (a subset of idiopathic inflammatory myopathies) is underrecognized but significant in patients with myositis, interstitial lung disease, arthritis, Raynaud's, and mechanic's hands (prevalence ~20-30 percent of myositis cases in rheumatology cohorts). Jo-1 is the most common antibody, with PL-7, PL-12, EJ, OJ less frequent. High morbidity from underdiagnosis in rural areas, limited myositis testing, overlap with connective tissue diseases or infections, and delayed immunosuppressive therapy leading to progressive lung fibrosis or disability. Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for confirming anti-synthetase syndrome and guiding prognosis. This diagnostic falls under autoimmune screening and targets patients with suspected myositis or ILD, addressing accurate detection to initiate corticosteroids, immunosuppressants, or rituximab. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing pulmonary complications. Its serum-based approach ensures reliable detection.**Other Names**: Synthetase Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Identified in 1980s; in India, prominence with increasing myositis registries.**Purpose**: The test screens for 5 parameters including anti-Jo-1 to guide anti-synthetase syndrome diagnosis, assess myositis-ILD risk, inform treatment.**Test Parameters**: 1. Anti-Jo-1, 2. Anti-PL-7, 3. Anti-PL-12, 4. Anti-EJ, 5. Anti-OJ.**Pretest Condition**: No fasting required; patients should report muscle weakness, joint pain, Raynaud's, mechanic's hands, or dyspnea.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on muscle weakness, joint pain, skin changes, lung symptoms, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated syndrome including lung fibrosis, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate anti-synthetase syndrome, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists or pulmonologists should be consulted for management.**Additional Supporting Tests**: CK levels, muscle biopsy, HRCT chest for confirmation.**Test Limitations**: May miss rare antibodies; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Myositis Studies India 2023. |
